Key Points
- Alpha Tau Medical CFO Raphi Levy sold 32,500 shares on June 3 at an average price of $10.83, totaling about $351,975. After the sale, he still owned 147,680 shares, a reduction of 18.04% in his stake.
- The stock was down 3.2% and opened at $10.24, near its 1-year high of $11.62. The company’s shares have risen well above both their 50-day and 200-day moving averages.
- Alpha Tau Medical reported a wider-than-expected quarterly loss, posting EPS of -$0.26 versus analyst estimates of -$0.13. Wall Street’s consensus view remains cautious overall, with an average rating of “Hold” and an average target price of $12.60.
Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) CFO Raphi Levy sold 32,500 shares of the firm's stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00. Following the completion of the sale, the chief financial officer directly owned 147,680 shares in the company, valued at $1,599,374.40. This represents a 18.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Alpha Tau Medical Trading Down 3.2%
Shares of DRTS opened at $10.24 on Friday. The firm's 50 day simple moving average is $8.55 and its 200 day simple moving average is $6.96. The company has a market capitalization of $924.98 million, a P/E ratio of -15.28 and a beta of 1.19. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. Alpha Tau Medical Ltd. has a 1-year low of $2.81 and a 1-year high of $11.62.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). Sell-side analysts forecast that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the stock. LADENBURG THALM/SH SH lifted their price target on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, May 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Citigroup lifted their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, March 11th. Barclays lifted their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an "overweight" rating in a research note on Thursday. Finally, Piper Sandler lifted their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a "neutral" rating in a research note on Tuesday, May 19th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $12.60.
Get Our Latest Stock Analysis on DRTS
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Trifecta Capital Advisors LLC bought a new stake in Alpha Tau Medical in the fourth quarter valued at $48,000. Envestnet Asset Management Inc. bought a new stake in Alpha Tau Medical in the third quarter valued at $62,000. Bank of America Corp DE boosted its holdings in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after acquiring an additional 21,677 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock valued at $116,000 after acquiring an additional 17,500 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in Alpha Tau Medical in the first quarter valued at $132,000. 2.65% of the stock is owned by hedge funds and other institutional investors.
Alpha Tau Medical Company Profile
(
Get Free Report)
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
